Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

11 Customer Reviews

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

    HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

  • U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f5UFAuOTBizszN M3TXWlAuPCCm NUezTohHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M4L0W|I3PzB{N{i0
HepG2 M4TuVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvXNE0yOCEQvF2= NH2zengxNTRiZB?= MUPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{PrWFI3PzB{N{i0
HT29 NVLLe4xUTnWwY4Tpc44hSXO|YYm= NHnX[I02OMLibl2= NGHM[mgzPC15MjDo MYHpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFQ5yqCqwrC= NUfjd2p3OjZ5MEK3PFQ>
HepG2 MnHFSpVv[3Srb36gRZN{[Xl? MXq1NOKhdk1? NYfJPJlnOjRvN{KgbC=> MV;pcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G|cHHz[UA{KGGodHXyJFI1yqCqwrC= M3Lx[VI3PzB{N{i0
HCC827 NEnNe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUX1NWE{PS95LkWvNVAhdk1? NXPKe5ZyPzMEoHi= NWHuc2hHTE2VTx?= NVLaWJBY\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MoLSNlY3PzV2OES=
A549  MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITiNVIyOC9zNT:yNEBvVQ>? M1PhVlczyqCq M1f5SWROW09? MkTk[Y5p[W6lZYOgeIhmKGGwdHnwdo9tcW[ncnH0bZZmKGWoZnXjeEBw\iCncnzveIlvcWJ? M3HUNFI3Pjd3NEi0
NCI-H460  MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHTeY0yOC9{MD:zNEBvVQ>? MVi3NuKhcA>? MV3EUXNQ M3;SVoVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk NVm1cmtROjZ4N{W0PFQ>
J89GFP NUPxRnFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP2ToZFVVORwrC= NF;ZXJJGSzVyPUS5Mlg2KMLzIEGyMlY2KG6P NGL1bXgzPjV4M{W2PC=>
THP89GFP MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrEUXNQyqB? NIDUTYJGSzVyPUG5MlM1KMLzIE[uOFMhdk1? NVjnOHR2OjZ3NkO1Olg>
SK-NEP-1 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPzNE4xOeLCk{GwMlAh|ryP M3\KUFI1KGh? MmLkSG1UV8Li MU\JR|UxRTd4LkO0JI5O M1LzS|I3OTd4MkG5
G401 NXXjS|FXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfuPW4xOC5yMfMAl|ExNjBizszN NFzqWpMzPCCq NYTlb5dkTE2VT9Mg MmrhTWM2OD1zNEOuNFIhdk1? M{fvV|I3OTd4MkG5
SK-NEP-1 NIHZXJpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3L1ZlUxKG6P M3\4WVHjiJN2IHS= MXzEUXNQyqB? MYny[YR2[2W|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> Mm\SNlYyPzZ{MUm=
G401 NYjWN45mS2WubDDWbYFjcWyrdImgRZN{[Xl? MnTtOVAhdk1? NEfjUXgy6oDVNDDk M3PLNmROW00EoB?= NWW1bHM2emWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ MljrNlYyPzZ{MUm=
SK-NEP-1 NHK5VndCeG:ydH;zbZMhSXO|YYm= MUO1NE8yODBibl2= NXnPPGs4OjRiaB?= NY\mbIZCTE2VT9Mg MYDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3\OXFI3OTd4MkG5
G401 NXvVT2hmSXCxcITvd4l{KEG|c3H5 NYi4VoF4PTBxMUCwJI5O MnHVNlQhcA>? MWPEUXNQyqB? MYnpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYDLeVBPOjZzN{[yNVk>
SK-NEP-1 M1vVbGZ2dmO2aX;uJGF{e2G7 Mm\TOVAwOTByIH7N NYHVT2ZWOjRiaB?= NXjES4pvTE2VT9Mg MoS5d4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>? M4LaNlI3OTd4MkG5
G401 MmLUSpVv[3Srb36gRZN{[Xl? MUm1NE8yODBibl2= NIPTZ5UzPCCq NYTvU2VkTE2VT9Mg M3XxVZNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? NUT2eJhEOjZzN{[yNVk>
SK-NEP-1 MlTMSpVv[3Srb36gRZN{[Xl? MVq1NE8yODBibl2= MXOyOEBp NYSxXJlRTE2VT9Mg MmDFbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> NV71c3AyOjZzN{[yNVk>
G401 MmTGSpVv[3Srb36gRZN{[Xl? NH34e2I2OC9zMECgcm0> MXiyOEBp MVHEUXNQyqB? MlTNbY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA> MWeyOlE4PjJzOR?=
RPMI 8226 NEDpUmZE\WyuIGP1dpZqfmGuIFHzd4F6 M4joXVIwPC94IH7N MmD6OFjjiImq Ml3SbY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>? MWOyOlAxODJ7Mh?=
OPM2 MoD2R4VtdCCVdYL2bZZidCCDc4PhfS=> MWeyM|QwPiCwTR?= Mne2OFjjiImq NUPIVm1ocW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= NV35W2tSOjZyMECyPVI>
U266 NEDlbYpE\WyuIGP1dpZqfmGuIFHzd4F6 NXn3UFBxOi92L{[gcm0> NHTvVIg1QOLCiXi= MWfpcoR2[2W|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp NF[3U2ozPjByMEK5Ni=>
H929 MVjD[YxtKFO3co\peoFtKEG|c3H5 NH3TZVAzNzRxNjDuUS=> NYD5[5k4PDkkgJno NWHFN4cxcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= MkHvNlYxODB{OUK=
RPMI 8226  NXPLRlM{SXCxcITvd4l{KEG|c3H5 MojCOQKBkW6P MV2yOE81QCCq NHzOeJpqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NH;UcJQzPjByMEK5Ni=>
HCC827 MmPQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYWxNEBvVQ>? MYm0PEBp NF[2TGtFVVOR NX\wZpVY\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MXeyOVk1PDZzNx?=
NCI-H23 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j0c|ExKG6P M{KxWFQ5KGh? MmTpSG1UVw>? MV\lcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>? NFv4TpQzPTl2NE[xOy=>
AML3 MnW3SpVv[3Srb36gRZN{[Xl? NWrzbZE4OC1zIN88US=> NX6xSJpCOjUEoHi= NFv2N5RqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MX[yOVYyOjl2MR?=
ML-1 M2jrTGZ2dmO2aX;uJGF{e2G7 M1TXZVAuOSEQvF2= M1:5[lI1yqCq MV;pcoR2[2W|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MoHSNlU3OTJ7NEG=
RPMI-8226vr10  MljiSpVv[3Srb36gRZN{[Xl? M3Gz[VAuOSEQvF2= NIrjfIIzPMLiaB?= NEfifJBqdmS3Y3XzJGRPSSCocnHncYVvfGG2aX;uxsBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NX3SWGp6OjV4MUK5OFE>
ML-1 MYXGeY5kfGmxbjDBd5NigQ>? MVmxJO69VQ>? M3HOOlI1yqCq MofWbY5kemWjc3XzJINie3Cjc3WtN{Bi[3Srdnn0fUA1NW[xbHS= MmL6NlU3OTJ7NEG=
RPMI-8226vr10  MUnGeY5kfGmxbjDBd5NigQ>? M{WzeFEh|ryP M3LvPVI1yqCq MVTpcoNz\WG|ZYOgZ4F{eGG|ZT2zJIFkfGm4aYT5JFIvPS2ob3zk MnjQNlU3OTJ7NEG=
SK-N-BE (2) MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nKT|I16oDLaB?= MYHJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? NH\pXZIzPTNyOEmxOi=>
SK-N-BE (2), PAN  MK MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjwdYRlOjUkgJno MmT1TWM2OD1zMESuNQKBkcLz4pEJO{45KG6P NYS5e3Y{OjV|MEi5NVY>
SK-N-BE (2), MK  PAN MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInGSXQzPOLCiXi= MnHOTWM2OD1|OEKuNQKBkcLz4pEJOFMvOiCwTR?= NY\ZT|NYOjV|MEi5NVY>
SK-N-AS MnvQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3nUoEzPOLCiXi= MoDBTWM2OD1|Nz6x5qCKyrIkgJmyMlQhdk1? NYPocXhvOjV|MEi5NVY>
SK-N-DZ MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXjN4szPOLCiXi= NXS2eVRIUUN3ME2xO{4y6oDLwsJihKkxNjRibl2= Ml\ENlU{ODh7MU[=
Caki-1 NET5ZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz5NVAwOjVxNUCgcm0> MkDwOFghcA>? NI\2ZVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NXfmVmZUOjV{N{mxPVE>
ACHN MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUixNE8zPS93MDDuUS=> M{T0dFQ5KGh? MoH2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{ MlrBNlUzPzlzOUG=
769-P MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXixNE8zPS93MDDuUS=> NEPuWG01QCCq NInnTYlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= MX6yOVI4QTF7MR?=
786-O  NIfMOHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTETXc4OTBxMkWvOVAhdk1? M{T0T|Q5KGh? MWDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? NGLoTYMzPTJ5OUG5NS=>
Caki-1 NUfITlFrSXCxcITvd4l{KEG|c3H5 M{nteVUxKG6P M4S1R|Q5KGh? M1yyNIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NU[ycZZzOjV{N{mxPVE>
ACHN M1LCW2Fxd3C2b4Ppd{BCe3OjeR?= MlixOVAhdk1? NGLEUXQ1QCCq M33EWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NX24NVZlOjV{N{mxPVE>
769-P M{j6XGFxd3C2b4Ppd{BCe3OjeR?= NFfENZU2OCCwTR?= MVW0PEBp NEG3[XRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHPvcYJqdmWmIILpeI9v[X[rch?= M4fSNVI2Ojd7MUmx
786-O  NU\rVHd7SXCxcITvd4l{KEG|c3H5 M{C0elUxKG6P M37oclQ5KGh? NVn2fnZ6cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= MoWwNlUzPzlzOUG=
Caki-1 NX3UO5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[4NlI2NzVyIH7N Mmr2OFghcA>? NF\IfnlFVVOR MVfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MmPKNlUyPzZ|NUS=
ACHN M1fp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe2NWIzPS93MDDuUS=> NUTYb|NZPDhiaB?= Mm\OSG1UVw>? MlrvbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MWCyOVE4PjN3NB?=
769-P MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfOS5UzPS93MDDuUS=> MVm0PEBp NXW2fpd6TE2VTx?= NGTXbIhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni NEXBTJMzPTF5NkO1OC=>
Caki-1 M3\pdGNwdG:weTDGc5Ju[XSrb36gRZN{[Xl? MmPhOVAhdk1? MUi3MVE1KGR? MXjEUXNQ MXTzeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MVqyOVE4PjN3NB?=
ACHN MWTDc4xwdnliRn;ycYF1cW:wIFHzd4F6 M2juNlUxKG6P NWHDN|dOPy1zNDDk M2XwPGROW09? MkLnd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NFP6flYzPTF5NkO1OC=>
769-P M2\VV2NwdG:weTDGc5Ju[XSrb36gRZN{[Xl? M3vUUlUxKG6P MYS3MVE1KGR? NUD6R3VYTE2VTx?= M3;yd5N2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh MmHQNlUyPzZ|NUS=
Caki-1 M32xVmFxd3C2b4Ppd{BCe3OjeR?= M2q4elUxKG6P NIPBW4o1QCCq M1zVUmROW09? MniybY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MnrWNlUyPzZ|NUS=
ACHN NF3LTnpCeG:ydH;zbZMhSXO|YYm= M{\4dVUxKG6P M4njcFQ5KGh? NVfkSXRJTE2VTx?= M1PlbYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUfnXoRHOjVzN{[zOVQ>
769-P M4PWWmFxd3C2b4Ppd{BCe3OjeR?= NVG1SWJ3PTBibl2= NHfhdFA1QCCq MlT0SG1UVw>? MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NWLHVIZFOjVzN{[zOVQ>
MDA-MB-231 MXTNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk> NHf4UHMyOMLibl2= M4rCSFPDqGR? MkHjSG1UVw>? M1v0OIFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= MWmyOFgyODR7Nx?=
BT-549 M1fDU21wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? MVqxNOKhdk1? MoDWN:Kh\A>? MnHlSG1UVw>? M1GwZoFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?= Mn;1NlQ5OTB2OUe=
MCF-7  M{nKZm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NIjJU4kyOMLibl2= NIi4NHo{yqCm MXjEUXNQ MWfhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MV2yOFgyODR7Nx?=
MCF-7 M1H0PWZ2dmO2aX;uJGF{e2G7 NF;rTY02NTVyIH7N M{[1WlI1KGh? MoDoSG1UVw>? MlO2doVlfWOnZDD0bIUhdGW4ZXygc4Yh\XiycnXzd4lwdiCxZjDFVu6yNCCSUjDhcoQhTm:6QUJCpC=> NILQXoIzPDN4NkSwOy=>
CTS NVvsUXo1SXCxcITvd4l{KEG|c3H5 MYSw5qCUPDBibl5CpC=> MkOyOFghcA>? MXrpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NEj1Oo4zPDJ2NESyPS=>
OCI-AML3  MUTBdI9xfG:|aYOgRZN{[Xl? NXLRVJNCOOLCk{SwJI5OyqB? MnfVOFghcA>? MmPibY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NYS3clhXOjR{NES0Nlk>
U937 Mo\IRZBweHSxc3nzJGF{e2G7 NX;4SWlZOOLCk{SwJI5OyqB? Ml3xOFghcA>? NEHycYxqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NYDq[4h5OjR{NES0Nlk>
PC3 M4iycWFxd3C2b4Ppd{BCe3OjeR?= M1;qR|AuOTByIH7N MnGxNlQwPDhiaB?= NWW1NIN2cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MmrqNlQyPjN{M{C=
PC3-AR MVHBdI9xfG:|aYOgRZN{[Xl? NGq2OmYxNTFyMDDuUS=> MnfjNlQwPDhiaB?= NWHWe2dYcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MUeyOFE3OzJ|MB?=
PC3 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYewMVExOCCwTR?= MVuyOE81QCCq NVqxNIFzcW6mdXPld{Bi[2O3bYXsZZRqd25ib3[gd5VjTzFicH;weYxifGmxbh?= MkGxNlQyPjN{M{C=
PC3-AR NYHMW4ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvT[ZlTOC1zMECgcm0> NUPJ[lZ2OjRxNEigbC=> M{HRdYlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgbY4hfGinIFeyUUBxcGG|ZR?= MljHNlQyPjN{M{C=
PC3 NIrkRlZHfW6ldHnvckBCe3OjeR?= MoK0NE0yODBibl2= Mke2NlQhcA>? MWfzeZBxemW|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?= MkHzNlQyPjN{M{C=
PC3-AR NY\tbJR[TnWwY4Tpc44hSXO|YYm= MV:wMVExOCCwTR?= MXuyOEBp NVGySllue3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4> NFf6OHozPDF4M{KzNC=>
OS-RC-2 MlXBR4VtdCCYaXHibYxqfHliQYPzZZk> MYCwMVExODBibl2= MlraNlQwPDhxN{KgbC=> NELSVGdFVVOR M4HJdYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYmyOFE1PDd|Nx?=
OS-RC-2 NGjobG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXS1NEBvVQ>? M2jZWFQ5KGh? NHTXcVRFVVOR NH;BUXdqdmS3Y3XzJGczN01iYYLy[ZN1 NYfXfGV6OjRzNES3N|c>
OS-RC-2 MkLwRZBweHSxc3nzJGF{e2G7 NVrNc2tUPTBibl2= NVLPPWpWPDhiaB?= M4q5R2ROW09? MlvYbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MlPMNlQyPDR5M{e=
SK-N-AS M37zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXThdoNmOOLCk{iwJI5O Mk[1OFghcA>? M{eyTWlEPTB;MkeuOEBvVQ>? NXra[mVYOjRyOUi3PVk>
SK-N-DZ MlXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXydmFROOLCk{iwJI5O NHLESnE1QCCq NHXFSYJKSzVyPUKxMlkhdk1? NUHYeWk6OjRyOUi3PVk>
SK-N-SH NH\FbllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Lhe|DjiJN6MDDuUS=> NXK2T2xqPDhiaB?= MVfJR|UxRTd{LkOgcm0> MUSyOFA6QDd7OR?=
SK-N-BE M{O1cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnNVnIx6oDVOECgcm0> NWDibHNsPDhiaB?= MnHWTWM2OD15NT60JI5O NHP5W3czPDB7OEe5PS=>
SK-N-AS NWrSZ2dESXCxcITvd4l{KEG|c3H5 MmjkNQKBmzhyIH7N MkHuOFghcA>? MnPvdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MYiyOFA6QDd7OR?=
SK-N-DZ MXXBdI9xfG:|aYOgRZN{[Xl? M{jJ[lDjiJN6MDDuUS=> NGOyTXA1QCCq MV3wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MlntNlQxQTh5OUm=
SK-N-SH NGHZPG5CeG:ydH;zbZMhSXO|YYm= MV2w5qCUPDBibl2= MUG0PEBp M3LXWJBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG|aHnvci=> MYKyOFA6QDd7OR?=
SK-N-BE MlXxRZBweHSxc3nzJGF{e2G7 NX3QdoU1OOLCk{SwJI5O NYi0b3JEPDhiaB?= NUHOUGdTeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v NGLmelIzPDB7OEe5PS=>
SK-N-AS MYnGeY5kfGmxbjDBd5NigQ>? NYrJcIdwOOLCk{iwJI5O NUDsdGVrPDhiaB?= NYjsWYV4cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>? MX2yOFA6QDd7OR?=
SK-N-DZ M{DBbmZ2dmO2aX;uJGF{e2G7 M2nENFDjiJN6MDDuUS=> M4\QdFQ5KGh? MVfpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ NWrRZlZMOjRyOUi3PVk>
SK-N-SH M3yxWmZ2dmO2aX;uJGF{e2G7 MofPNQKBmzRyIH7N MXi0PEBp MlnjbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> MViyOFA6QDd7OR?=
SK-N-BE MmnFSpVv[3Srb36gRZN{[Xl? NGO5NGUx6oDVNECgcm0> M1PNWlQ5KGh? M3P3VIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MYSyOFA6QDd7OR?=
HCC-LM3 NF\RbFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljDNU0yODByIH7N M4K2SlI1NzR6L{eyJIg> M4TmXmROW09? MlfYbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXqyOFA6Ozl3Nh?=
HepG2 NW\keXhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPqNU0yODByIH7N NFjnToszPC92OD:3NkBp M4rKW2ROW09? MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUjvbYNlOjRyOUO5OVY>
SMMC-7721 NFPuS3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn0fVkyNTFyMECgcm0> MYOyOE81QC95MjDo M2TPSmROW09? NFG3V2RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlX1NlQxQTN7NU[=
HCC-LM3 MYfBdI9xfG:|aYOgRZN{[Xl? Ml;jOVAhdk1? MVe0PEBp M4D0b2ROW09? MmfybY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> Mn;DNlQxQTN7NU[=
HepG2 NH7GUHBCeG:ydH;zbZMhSXO|YYm= NILwTm82OCCwTR?= NGPGdGU1QCCq NHG4Nm5FVVOR MoTSbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5JIlvKGFiY3HzdIF{\S2mZYDlcoRmdnRibXHucoVzKGK7IHPs[YF3[WenIH;mJINie3Cjc3XzJFMtKDhiYX7kJFk> NYK2[ZpyOjRyOUO5OVY>
SMMC-7721 NYDZfll1SXCxcITvd4l{KEG|c3H5 M{TnUlUxKG6P MVW0PEBp NUDGV4xjTE2VTx?= M1;OW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 NVPGSnNROjRyOUO5OVY>
HCC-LM3 NFfDNplHfW6ldHnvckBCe3OjeR?= MlXzOVAwOTByIH7N NXfvNZdEOjRiaB?= M13xPGROW09? NG\nW5ll\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NFPCOnkzPDB7M{m1Oi=>
HepG2 NW\nZ5k{TnWwY4Tpc44hSXO|YYm= MWe1NE8yODBibl2= Mn;ONlQhcA>? MVPEUXNQ MV\k[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyLWPURXQ{KGGwZDDwMWFsfMLi NWPXO2x{OjRyOUO5OVY>
SMMC-7721 NV7NcXdqTnWwY4Tpc44hSXO|YYm= NH3kNFk2OC9zMECgcm0> NYnkfIlwOjRiaB?= NUHSR5VCTE2VTx?= NI[zcpBl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR|IHHu[EBxNUGtdNMg NWDYRldbOjRyOUO5OVY>
HCC-LM3 M3nUSWZ2dmO2aX;uJGF{e2G7 MV[1NE8yODBibl2= M13VU|I1KGh? M1nte2ROW09? M3vjUYRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25? NVHxU5VMOjRyOUO5OVY>
HepG2 MmXzSpVv[3Srb36gRZN{[Xl? NYjSWFltPTBxMUCwJI5O NGDuNXkzPCCq M{CxTWROW09? NGP6e25ld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NG\6TIUzPDB7M{m1Oi=>
SMMC-7721 NWfFPFV1TnWwY4Tpc44hSXO|YYm= NGTOTVU2OC9zMECgcm0> NYLYV4l5OjRiaB?= MWTEUXNQ NUPubHhF\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NEPnWnozPDB7M{m1Oi=>
FaDu MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTTelQyODEkgJXuUS=> NEXQVpY5NzFyL{GyJIg> MUXkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? MoXHNlQxOjZ2OEK=
FaDu M1TKZ2Z2dmO2aX;uJGF{e2G7 NF:0RmgyODEkgJXuUS=> NUDZNIpQOi92L{ivNVIhcA>? Mnr5bY5lfWOnZDDwNlFY[WZzL1PpdFHDqGW6cILld5Nqd25? NXPneop5OjRyMk[0PFI>
PC-3  MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe3UJhbOC1zMDFOwG0> MYSyOE81QC95MjDo M2XOe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mlj2NlM6QTF{MU[=
LNCaP NULvOHdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnnXZJKOC13IN88US=> M33mflI1NzR6L{eyJIg> NVm2d2dWcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NFS3RZgzOzl7MUKxOi=>
RWPE-1  NFH6cmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDRNE0zOCEQvF2= MVKyOE81QC95MjDo NVTjXWR1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV\Beo5WOjN7OUGyNVY>
Capan-1 MmPLSpVv[3Srb36gRZN{[Xl? M4XDRVI2NzVyL{GwNEBvVQ>? MUS4M|I1NzR6IHi= M2\1SmROW09? MYrkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p MUCyN|kzOjh6Nh?=
L3.6pl M4\oNWZ2dmO2aX;uJGF{e2G7 NF65T|AzPS93MD:xNFAhdk1? MYO4M|I1NzR6IHi= Mo\SSG1UVw>? M{nrSoRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= NHLiUW0zOzl{Mki4Oi=>
CFPAC-1  MlzRSpVv[3Srb36gRZN{[Xl? MmLaNlUwPTBxMUCwJI5O NFvNT3o5NzJ2L{S4JIg> NHruVm9FVVOR MXrkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p M2XpT|I{QTJ{OEi2
Capan-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYqyOU82OC9zMECgcm0> MmTIOFghcA>? NILqbVZFVVOR NULkfGpZemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{XHeVI{QTJ{OEi2
L3.6pl M4fyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfrWm9oOjVxNUCvNVAxKG6P M4\ESVQ5KGh? MUjEUXNQ NUf2SYJYemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NGPNbXczOzl{Mki4Oi=>
CFPAC-1  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX6NlUwPTBxMUCwJI5O NF\6bWg1QCCq MnnpSG1UVw>? NU[zdZpOemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NH\BcmkzOzl{Mki4Oi=>
Capan-1 MWnBdI9xfG:|aYOgRZN{[Xl? NEnLPHAzPS93MD:xNFAhdk1? M3HZS|Q5KGh? MknESG1UVw>? M3PJS4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHvHSJkzOzl{Mki4Oi=>
L3.6pl MnXZRZBweHSxc3nzJGF{e2G7 Ml70NlUwPTBxMUCwJI5O MV:0PEBp MmjJSG1UVw>? MX3pcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYOyN|kzOjh6Nh?=
CFPAC-1  MlH6RZBweHSxc3nzJGF{e2G7 M{PJU|I2NzVyL{GwNEBvVQ>? NWTiSHJKPDhiaB?= MUPEUXNQ NGfFNnpqdmS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4XVdFI{QTJ{OEi2
HN22 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqwMVIxKG6P NYjUXIE6OjRxNEigbC=> NHrNbI1FVVOR M1;OWolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> NGjldY4zOzh5N{KzOS=>
HSC4  MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDSTGM1OC1{MDDuUS=> NHfk[lAzPC92ODDo NUnI[WpYTE2VTx?= NFnmdIlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NFXHdYUzOzh5N{KzOS=>
HN22 Mor0RZBweHSxc3nzJGF{e2G7 MVmwMVIxKG6P MlnVOFghcA>? NG\ENoFFVVOR MWrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3HSVFI{QDd5MkO1
HSC4  M{LZcGFxd3C2b4Ppd{BCe3OjeR?= M2fPNVAuOjBibl2= NWjme5FTPDhiaB?= MnKwSG1UVw>? M3S3VYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NV\NVnd[OjN6N{eyN|U>
HN22 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUWwMVIxKG6P MVu0PEBp M3\RbGROW09? M{nVdYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> Mk\iNlM5Pzd{M{W=
HSC4  MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG3NE0zOCCwTR?= NHjZW5E1QCCq NX7aVGRmTE2VTx?= MnPabY5lfWOnczDHNUBxcGG|ZTDj[YxtKGO7Y3zlJIFzemW|dNMg MojlNlM5Pzd{M{W=
HN22 M4\oOWZ2dmO2aX;uJGF{e2G7 Ml7wNE0zOCCwTR?= NXfGRpFJPDhiaB?= MnrwSG1UVw>? MnLqd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg M1H4SFI{QDd5MkO1
HSC4  MULGeY5kfGmxbjDBd5NigQ>? MVGwMVIxKG6P NWXXU|FyPDhiaB?= MYfEUXNQ M3jZOZN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> M4rs[FI{QDd5MkO1
Cal62 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\CZm9OUUN3ME2zN{DDuSB2IH7N MUWyN|gzPDB4NB?=
Hth7 MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID3OHlKSzVyPUG1JOKyKDJibl2= MnzUNlM5OjRyNkS=
Hth83 NWfCSnRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTLcodKSzVyPUO0JOKyKDVibl2= MWqyN|gzPDB4NB?=
C643 Ml3qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\GfWlEPTB;N{GgxtEhOTBibl2= NG\4RlUzOzh{NEC2OC=>
SW1736 NFW2U|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vjcmlEPTB;M{WgxtEhQCCwTR?= M3X4U|I{QDJ2ME[0
T241 M1XiOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTZ3INMxJFchdk1? NIPxZmozOzh{NEC2OC=>
T351 NUHUWIttT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVyINMxJFExKG6P NVzJcnJmOjN6MkSwOlQ>
BHP2-7 NUXBWFFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rjNGlEPTB;M{egxtEhPiCwTR?= M4DpNFI{QDJ2ME[0
T238 NWLXW5BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnmRoVGUUN3ME2xMFUxOCEEsTCyNFAhdk1? MYCyN|gzPDB4NB?=
HCT8 NV\TVHJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3j6dVczKGh? M3HDSGROW09? M3viN2lEPTB;MUKuPgKBkcLz4pEJNU46KG6P M3vMTVI{Ojl7M{i4
H630 NXrWfFFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXm3NkBp NX72SYxWTE2VTx?= MlXtTWM2OD1zMj605qCKyrIkgJmzMlEhdk1? M{K1SFI{Ojl7M{i4
cH630 5-FU-res MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDXZ4V2PzJiaB?= NE\od|NFVVOR Mkm1TWM2OD1zNT615qCKyrIkgJmxMlIhdk1? M{HTZVI{Ojl7M{i4
HCT116 M4PFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUG3NkBp MkDOSG1UVw>? MnLlTWM2OD1zMD635qCKyrIkgJmyMlIhdk1? MlzaNlMzQTl|OEi=
HCT116 p53−/− M2PtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQO|IhcA>? Ml24SG1UVw>? NXL6RZdTUUN3ME24MlbjiIoEsfMAjVEvPyCwTR?= NGnxW2UzOzJ7OUO4PC=>
dHCT116 p21−/− MmPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlm4O|IhcA>? M1vpbGROW09? NX7hZop6UUN3ME21MlnjiIoEsfMAjVEvOyCwTR?= NFPIXXUzOzJ7OUO4PC=>
HT29 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NkBp MmXuSG1UVw>? MofETWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? NWnaR|JLOjN{OUmzPFg>
LoVo NXzQRXhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITpWpU4OiCq MmH2SG1UVw>? MmDrTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? M1\VVVI{Ojl7M{i4
RKO NV\yUJdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO0O|IhcA>? NFLlW4FFVVOR MljJTWM2OD15LkpihKnDueLCiUKuNkBvVQ>? NHrrVWczOzJ7OUO4PC=>
SW480 NYDBc3NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TjUlczKGh? MVrEUXNQ MWDJR|UxRTF5LkZihKnDueLCiUCuPEBvVQ>? Mm\6NlMzQTl|OEi=
eSW620 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGD3ZWk4OiCq NYq5PJNoTE2VTx?= MkXvTWM2OD17LkJihKnDueLCiUKuNUBvVQ>? MYWyN|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02802163 Not yet recruiting Multiple Myeloma H. Lee Moffitt Cancer Center and Research Institute|Novartis|Amgen April 30, 2017 Phase 1|Phase 2
NCT02654990 Recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 27, 2016 Phase 2
NCT02890069 Recruiting Colorectal Cancer|Non-small Cell Lung Carcinoma (Adenocarcinoma)|Triple Negative Breast Cancer Novartis Pharmaceuticals|Novartis October 26, 2016 Phase 1
NCT01802879 Active, not recruiting Hematologic Neoplasms Novartis Pharmaceuticals|Novartis June 24, 2013 Phase 2
NCT00532675 Active, not recruiting Multiple Myeloma Novartis Pharmaceuticals|Novartis April 22, 2008 Phase 1
NCT02961816 Not yet recruiting Lymphoma M.D. Anderson Cancer Center February 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

Related Antibodies

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID